NCT00920946View on ClinicalTrials.gov

A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease

PHASE3CompletedINTERVENTIONAL

Enrollment

403

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

July 31, 2011

Conditions

Huntington Disease

Interventions

DRUG

Dimebon

20 mg Dimebon orally TID

OTHER

Placebo

Orally TID

Trial Locations (37)

10032

New York

14620

Rochester

15213

Pittsburgh

19107

Philadelphia

27157

Winstom-Salem

27705

Durham

32610

Gainsville

33136

Miami

43210

Columbus

44195

Cleveland

46202

Indianapolis

53226

Milwaukee

55427

Golden Valley

63110

St Louis

66160

Kansas City

67206

Wichita

83702

Boise

85259

Scottsdale

92161

La Jolla

92697

Irvine

94143

San Francisco

95616

Davis

97201

Portland

02129

Charlestown

Unknown

Wentworthville

Melbourne

Perth

Vancouver

London

Montreal

Copenhagen

Oberer Eslebberg

Aachen

Bochum

Hamburg

Stockholm

Birmingham

Sponsors

Lead Sponsor

Medivation, Inc.

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

Medivation, Inc.

INDUSTRY

NCT00920946 - A Safety and Efficacy Study of Dimebon in Patients With Huntington Disease | Biotech Hunter | Biotech Hunter